Schizophrenia

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Evidencia revisada por última vez: 20 Feb 2026
Tema actualizado por última vez: 21 Mar 2025

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • auditory hallucinations
  • delusions
  • avolition
  • anhedonia
  • asocial behavior
  • affective blunting
  • alogia
  • cognitive deficits
  • somatization
Todos los datos

Otros factores de diagnóstico

  • lack of insight (anosognosia)
  • bizarre or disorganized behavior
  • tangentiality and looseness of association (derailment)
  • circumstantiality
  • pressured speech
  • distractible speech
  • depression
  • suicidality
  • anxiety
  • elation
  • incongruent affect
  • verbigeration
  • perseveration
  • word salad
  • derealization
  • nonauditory hallucinations
  • déjà-vu
  • stilted goal-directed behaviors
  • catatonic symptoms
  • "soft" neurologic deficits
Todos los datos

Factores de riesgo

  • family history of schizophrenia
  • increasing paternal age
  • obstetric complications
  • cannabis use
  • low IQ
  • motor dysfunction
  • psychological stress
  • childhood abuse
  • migrant status
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • clinical diagnosis
Todos los datos

Pruebas diagnósticas que deben considerarse

  • MRI/CT head
  • serum HIV enzyme-linked immunosorbent assay
  • serum rapid plasma reagin (RPR) test
  • CBC including absolute neutrophil count (ANC)
  • drug toxicology screen
  • BUN and electrolytes
  • liver function tests
  • thyroid-stimulating hormone
  • pregnancy test
  • genetic testing
Todos los datos

Algoritmo de tratamiento

Inicial

at risk of developing psychosis

Agudo

acute psychotic episode

En curso

chronic symptoms

treatment-resistant schizophrenia

Colaboradores

Consejeros especializados

Xiaoduo Fan, MD, MPH, MSc

Professor of Psychiatry

Director, UMass MIND

UMass Memorial Health/UMass Chan Medical School

Worcester

MA

Divulgaciones

XF has received research support from Otsuka, Roche, Intra-Cellular Therapies, Avanir, and Janssen. XF holds a patent on "combination treatment for neuropsychiatric disorders" (USPTO patent # 11,331,319).

Agradecimientos

Dr Xiaoduo Fan would like to gratefully acknowledge Dr Adrian Preda and Dr Robert G. Bota, previous contributors to this topic.

Divulgaciones

AP and RGB declare that they have no competing interests.

Revisores por pares

David Taylor, PhD

Chief Pharmacist

South London and Maudsley NHS Foundation Trust

London

UK

Divulgaciones

DT declares that he has no competing interests.

Joel Yager, MD

Professor

Department of Psychiatry

University of New Mexico School of Medicine

Albuquerque

NM

Divulgaciones

JY declares that he has no competing interests.

Kemal Sagduyu, MD

Professor of Psychiatry

University of Missouri Kansas City

Kansas City

MO

Disclosures

KS declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Full text

American Psychiatric Association. ​The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2021.Full text

Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Schizoaffective disorder
    • Schizophreniform disorder and brief psychotic disorder
    • Substance-induced psychotic disorder
    More Differentials
  • Guidelines

    • Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5-TR)
    • Evidence-based guidelines for the pharmacological treatment of schizophrenia
    More Guidelines
  • Patient information

    Schizophrenia: what is it?

    Schizophrenia: questions to ask your doctor

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer